A Phase 2 interventional study of Recombinant Human C1 Inhibitor in Genetic Disorders and Hereditary Angioedema, sponsored by Pharming Technologies B.V.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-26.
Sponsored by Pharming Technologies B.V. (part of Pharming Group N.V.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. Complement C1 Inhibitor Protein · Angioedemas, Hereditary.
Among the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary, this one is the 12th largest by enrollment, is the only one that started in 2009, is one of 2 in phase 2, and was the 11th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →None of the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →
Complement C1 Inhibitor Protein: first FDA approval 2014 (Ruconest), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 10 · Phase 4 2
First in 2004; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 32 across the 17 interventional studies. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 17 have an industry lead sponsor. The 9 most frequent:
This study is registered under Pharming Technologies B.V., one of the names counted as Pharming Group N.V.. Under that name alone:
Pharming Technologies B.V. is the lead sponsor of 22 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Pharming Group N.V. has 8 studies filed under Angioedemas, Hereditary — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Hereditary angioedema ("HAE") is a disease characterized by recurrent tissue swelling affecting various body locations. Recent literature shows that patients with frequent attacks may benefit from long-term prophylaxis. This study aims to evaluate the safety and prophylactic effect of weekly administrations of 50 IU/kg recombinant C1 Inhibitor ("rhC1INH").
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
This study's enrollment of 25 is below the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Browse Angioedemas, Hereditary studies →Pharming Technologies B.V. is the lead sponsor of 22 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Compared within Angioedemas, Hereditary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Genetic Diseases, Inborn. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weekly administration of 50 IU/kg Recombinant Human C1 Inhibitor
Drug: Recombinant Human C1 Inhibitor
Drug pages: Complement C1 Inhibitor Protein · Conestat alfa · C1 esterase inhibitor (human)
50 IU/kg "rhC1INH", "IV" injection over 4 to 5 minutes, once weekly over an 8-week treatment period.
Also known as: "rhC1INH", Ruconest
HAE Attacks/Week
Prior to the treatment period, patients enrolled in the study, were asked about the amount of "HAE" attacks in the past 2 years, (calculated to attacks/week), this number is defined as "Historical". During the treatment period, patients received a dose of 50 IU/kg of "rhC1INH" administered by slow "IV" injection over 4 to 5 minutes, once a week during an eight week period. The amount of attacks during this period is defined as "Prophylaxis" (calculated to attacks/week).
Time frame: 8 weeks
The Evaluation of Pharmacokinetic/ Pharmacodynamic ("PK/PD")Parameters.
"PK/PD" parameters will be based on concentration time curves after the 1st and 8th "rhC1INH" administration.(ratio visit 8/ visit 1, based on the area under the curve from baseline up to 4 hours after administration (AUC 0-4)
Time frame: 8 weeks
Patients with a history of frequent attacks, defined as "HAE" attacks occurring at least every two weeks were included in the study.
| Milestone | Recombinant Human C1 Inhibitor |
|---|---|
| Started | 25 |
| Completed | 25 |
| Not completed | 0 |
Prior to the treatment period, patients enrolled in the study, were asked about the amount of "HAE" attacks in the past 2 years, (calculated to attacks/week), this number is defined as "Historical". During the treatment period, patients received a dose of 50 IU/kg of "rhC1INH" administered by slow "IV" injection over 4 to 5 minutes, once a week during an eight week period. The amount of attacks during this period is defined as "Prophylaxis" (calculated to attacks/week).
| attacks/week | Recombinant Human C1 Inhibitor |
|---|---|
| Historical | 0.9 (0.51 to 1.30) |
| Prophylaxis | 0.4 (0.27 to 0.56) |
"PK/PD" parameters will be based on concentration time curves after the 1st and 8th "rhC1INH" administration.(ratio visit 8/ visit 1, based on the area under the curve from baseline up to 4 hours after administration (AUC 0-4)
| ratio | Recombinant Human C1 Inhibitor |
|---|---|
| Functional C1 Inhibitor level | 1.06 (0.98 to 1.14) |
| Antigenic C1 Inhibitor level | 1.02 (0.91 to 1.15) |
| C4 level | 1.00 (0.74 to 1.33) |
Collected over Treatment emergent adverse events ("TEAEs") were defined as events with start from onset of study drug administration. All Serious Adverse Events("SAEs")are listed.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Recombinant Human C1 Inhibitor | — | 2/25 (8%) | 2/25 (8%) |
| Event | Recombinant Human C1 Inhibitor |
|---|---|
| AppendicitisInfections and infestations | 1/25 |
| Laryngeal edemaRespiratory, thoracic and mediastinal disorders | 1/25 |
| Event | Recombinant Human C1 Inhibitor |
|---|---|
| Anaemia-mildBlood and lymphatic system disorders | 1/25 |
| Anaemia-moderateBlood and lymphatic system disorders | 1/25 |
| Age, Categorical(Participants) | Recombinant Human C1 Inhibitor |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 25 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Recombinant Human C1 Inhibitor |
|---|---|
| Female | 20 |
| Male | 5 |
The record gives a start of Jun 2009, a primary completion of Mar 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Complement C1 Inhibitor Protein · Conestat alfa · C1 esterase inhibitor (human)